Followers | 63 |
Posts | 8502 |
Boards Moderated | 0 |
Alias Born | 01/10/2014 |
Monday, December 30, 2019 4:33:03 PM
2019 Q4 has been a great quarter for biotech investors and more M&A deals are expected in 2020.
With the FDA approval of Oxbryta, GBT is the perfect acquisition candidate for treating sickle cell disease.
Global Blood Therapeutics (GBT) - $9B
With a market cap of $4.9B, Global Blood Therapeutics is engaged in the innovation and commercialization of drugs to serve the needs of sickle cell disease (NYSE:SCD). SCD is an inherited blood disorder caused by a genetic mutation in the beta-chain of hemoglobin, leading to the formation of abnormal hemoglobin known as sickle hemoglobin. GBT went up 60% over 3 weeks since the company confirmed FDA approval of Oxbryta (voxelotor), company's main drug to treat sickle cell disease in adults and children 12 years of age and older.
Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Following suit, the European Medicines Agency (NYSEMKT:EMA) has also included voxelotor in its Priority Medicines (PRIME) program, while the European Commission (NYSE:EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD. Based on GBT's EHA corporate update in June, Oxbryta is addressing the needs of over 100,000 SCD patients in U.S. and 60,000 patients in Europe. The annual cost of SCD care is $200,000 per patient. An approved drug means R&D risks are largely absent and GBT is attractive to large Biopharma companies which seek to expand their drug pipelines without development risks.
Additionally, GBT started HOPE-KIDS2 which is to confirm there is a decreased risk of stroke for children 2 to 15 years old with Oxbryta. GBT also announced a collaboration with Syros Pharmaceuticals (SYRS) to discover, develop and commercialize novel therapies for sickle cell disease and beta thalassemia. On Dec 18, GBT secured $150M non-dilutive term loan to enhance its cash position for further development and commercialization, which clears any near-term dilution risks and places company in a great spot to negotiate a good deal with potential acquirers.
https://seekingalpha.com/article/4314536-5-best-mid-cap-biotech-acquisition-targets
Statements made are only my opinion. Do your own DD in order to make your Investment decisions.
Recent GBT News
- GROUPE BMTC INC. ANNONCE L'ACQUISITION D'UN CENTRE DE DISTRIBUTION À TERREBONNE AFIN DE GÉNÉRER DES REVENUS LOCATIFS À LONG TERME • PR Newswire (Canada) • 04/15/2024 11:30:00 PM
- BMTC GROUP INC. ANNOUNCES THE ACQUISITION OF A DISTRIBUTION CENTER TO GENERATE LONG-TERM RENTAL INCOME • PR Newswire (Canada) • 04/15/2024 11:30:00 PM
- GROUPE BMTC INC. ANNONCE LE RENOUVELLEMENT DE SON OFFRE DE RACHAT DANS LE COURS NORMAL DES ACTIVITÉS VISANT SES ACTIONS ORDINAIRES • PR Newswire (Canada) • 04/10/2024 11:30:00 PM
- BMTC GROUP INC. ANNOUNCES THE RENEWAL OF ITS NORMAL COURSE ISSUER BID TO ACQUIRE COMMON SHARES • PR Newswire (Canada) • 04/10/2024 11:30:00 PM
- GROUPE BMTC INC. ANNONCE SES RÉSULTATS FINANCIERS POUR LA PÉRIODE DE NEUF MOIS TERMINÉE LE 31 OCTOBRE 2023 • PR Newswire (Canada) • 12/12/2023 12:30:00 AM
- BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE NINE MONTH PERIOD ENDED OCTOBER 31st, 2023 • PR Newswire (Canada) • 12/12/2023 12:30:00 AM
- BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE SEMESTER ENDED JULY 31st, 2023 • PR Newswire (Canada) • 09/07/2023 11:30:00 PM
- GROUPE BMTC INC. ANNONCE SES RÉSULTATS FINANCIERS POUR LE SEMESTRE TERMINÉ LE 31 JUILLET 2023 • PR Newswire (Canada) • 09/07/2023 11:30:00 PM
- BMTC GROUP INC. ANNOUNCES THE ELECTION OF DIRECTORS • PR Newswire (Canada) • 06/08/2023 09:32:00 PM
- GROUPE BMTC INC. ANNONCE L'ÉLECTION DES ADMINISTRATEURS • PR Newswire (Canada) • 06/08/2023 09:30:00 PM
- BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE QUARTER ENDED APRIL 30th, 2023 • PR Newswire (Canada) • 06/08/2023 06:00:00 PM
- GROUPE BMTC INC. ANNONCE SES RÉSULTATS FINANCIERS POUR LE TRIMESTRE TERMINÉ LE 30 AVRIL 2023 • PR Newswire (Canada) • 06/08/2023 06:00:00 PM
- Tanguay just moved in and is rolling out its experience across the province with 11 new stores • PR Newswire (Canada) • 05/16/2023 12:30:00 PM
- Tanguay arrive dans le décor et déploie son expérience à l'échelle de la province avec 11 nouveaux magasins • PR Newswire (Canada) • 05/16/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM